Update shared on12 Oct 2025
Fair value Increased 3.65%Tempus AI's fair value estimate has been raised by analysts from $74.82 to $77.55 per share. This reflects optimism about improved revenue growth and updated market outlooks.
What's in the News
- Tempus AI selected by ARPA-H to provide AI-enabled testing and contract research services for the ADAPT program, aiming to advance adaptive cancer therapies (Key Developments).
- Tempus receives FDA 510(k) clearance for two products: its RNA-based Tempus xR IVD device and the updated Tempus Pixel AI-powered cardiac imaging platform, enhancing clinical diagnostic and imaging capabilities (Key Developments).
- Parse Biosciences welcomes Tempus to its Certified Service Provider Program, expanding access to single cell and multi-omics technologies for scalable research (Key Developments).
- Northwestern Medicine expands its collaboration with Tempus and becomes the first health system to integrate Tempus’ generative AI clinical co-pilot within its electronic health record system (Key Developments).
- Class action lawsuit filed against Tempus AI alleges failures in financial disclosures and questions about the credibility of management and business practices, leading to a significant drop in stock price (Key Developments).
Valuation Changes
- The Fair Value Estimate has risen slightly from $74.82 to $77.55 per share.
- The Discount Rate increased marginally from 7.30% to 7.34%.
- Revenue Growth projection improved from 29.69% to 30.94%.
- The Net Profit Margin remains essentially unchanged, moving from 12.74% to 12.73%.
- The Future P/E Ratio has edged up from 74.10x to 74.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.